NoPrescriptionDrugstore.com Order Status FAQ Online Drugstore Affiliate Program Contact NoPrescriptionDrugstore.com No Prescription Drugs Newsletter Refer a Friend
 
Thursday, November 20, 2008  
Sosei And (No Prescription) NeuroSolutions Present Further Data On NSL-043/SD118 At The Society For Neuroscience 38th Annual Meeting
Sosei And NeuroSolutions Present Further Data On NSL-043/SD118 At The Society For Neuroscience 38th Annual Meeting
NeuroDiscovery Ltd (ASX: NDL), a specialty neuroscience service provider and drug development Company, and Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), a leading international biopharmaceutical company, announce that NeuroSolutions is presenting further pivotal pre-clinical efficacy data for NSL-043/SD118. This investigational drug is a potential therapy for neuropathic pain and has successfully completed Phase I clinical studies and is now ready for Phase II studies.
Source: www.medicalnewstoday.com

More Than 100 Scientific Abstracts Presented By GU/GUMC Researchers At Neuroscience 2008
Research highlights include how we see faces in our dreams, understanding how young and old adults learn, helping stroke survivors speak using fMRI, an explanation about autism and facial recognition and ways to possibly forestall Parkinson's disease.
Source: www.medicalnewstoday.com

Pfizer Drops Application To Switch Viagra 50mg To Non-Prescription Status In Europe
Pfizer announced today that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from 'prescription only' to 'non-prescription' in the European Union (EU). Viagra is a well established oral medication for the treatment of erectile dysfunction (ED) and all current doses of Viagra will continue to be available to patients by prescription from their doctor.
Source: www.medicalnewstoday.com

Pharmos Announces Clinical Results From Phase 2a Trial Of Topical Diclofenac NanoEmulsion Cream
Pharmos Corporation (Nasdaq: PARS) announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Diethanolamine. The multi-center, randomized, double-blinded, placebo controlled study evaluated the safety and efficacy of the Company's 3% Diclofenac Diethanolamine NanoEmulsion cream in 104 patients with chronic pain due to osteoarthritis of the knee.
Source: www.medicalnewstoday.com

New Scan Spots Beginning of Bone Problems in Anorexics
Title: New Scan Spots Beginning of Bone Problems in Anorexics
Category: Health News
Created: 11/20/2008 2:00:00 AM
Last Editorial Review: 11/20/2008
Source: www.medicinenet.com

Subscribe to Posts [Atom]

Home | Order Status | FAQ | Affiliates | Contact us | Newsletter | Refer a Friend

© 2004 Online Pharmacy. All Rights Reserved.